Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | PTAFR | P25105 | 12/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86872 | 0.98 | DNMT1 (0.53) | DNMT1RAD52UHRF1SIGMAR1HDAC4 | |
| SCHEMBL7326935 | 0.80 | DNMT1 (0.51) | DNMT1RAD52UHRF1HDAC4HDAC8 | |
| SCHEMBL7326253 | 0.80 | DNMT1 (0.51) | DNMT1RAD52UHRF1HDAC4HDAC8 | |
| SCHEMBL28700929 | 0.76 | DNMT1 (0.37) | DNMT1RAD52UHRF1SIGMAR1HDAC4 | |
| SCHEMBL2260946 | 0.76 | PTAFR (0.41) | DNMT1RAD52UHRF1HDAC4HDAC8 | |
| Bromide SCHEMBL2260972 | 0.75 | HDAC8 (0.56) | HDAC4HDAC8PTAFR | |
| SCHEMBL12765021 | 0.73 | DNMT1 (0.44) | DNMT1RAD52UHRF1SIGMAR1HDAC4 | |
| SCHEMBL86634 | 0.73 | MEN1 (0.45) | DNMT1RAD52UHRF1HDAC4HDAC8 | |
| SCHEMBL2258835 | 0.73 | HDAC8 (0.57) | HDAC4HDAC8PTAFR | |
| Bromide SCHEMBL81705 | 0.72 | LGMN (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | SIGMAR1 4615/4885DNMT1 2491/4885RAD52 3514/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | SIGMAR1 4491/4885DNMT1 3328/4885RAD52 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.